Matinas BioPharma (NYSEAMERICAN:MTNB – Get Free Report) is scheduled to be issuing its quarterly earnings data on Tuesday, October 31st. Matinas BioPharma (NYSEAMERICAN:MTNB – Get Free Report) last announced its quarterly earnings results on Wednesday, August 9th. The company reported ($0.03) EPS for the quarter. Matinas BioPharma had a negative return on equity of 60.91% […]
This feature is going to take a closer look at five stocks look now!
Catheter Precision Inc. The United States-based medical device company is best known for its work on improving the lives of.
Matinas BioPharma (MTNB) Announces Patient with Candida krusei Infection in Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
By Chris Wack Matinas BioPharma shares doubled to 31 cents after the company completed the clinical resolution of a patient's recurrent hemorrhagic cystitis.